Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

IncobotulinumtoxinA Efficacy and Safety in Adults with Upper-Limb Spasticity Following Stroke: Results from the Open-Label Extension Period of a Phase 3 Study.

Marciniak C, Munin MC, Brashear A, Rubin BS, Patel AT, Slawek J, Hanschmann A, Hiersemenzel R, Elovic EP.

Adv Ther. 2019 Jan;36(1):187-199. doi: 10.1007/s12325-018-0833-7. Epub 2018 Nov 27.

2.

Burnout in neurology: Extinguishing the embers and rekindling the joy in practice.

Brashear A, Vickrey BG.

Neurology. 2018 Nov 13;91(20):907-908. doi: 10.1212/WNL.0000000000006520. Epub 2018 Oct 10. No abstract available.

PMID:
30305444
3.

Gender bias in American Academy of Neurology recognition awards?

Graves JS, Brashear A.

Neurology. 2018 Aug 14;91(7):291-292. doi: 10.1212/WNL.0000000000006025. Epub 2018 Jul 20. No abstract available.

PMID:
30030327
4.

Injectable DaxibotulinumtoxinA in Cervical Dystonia: A Phase 2 Dose-Escalation Multicenter Study.

Jankovic J, Truong D, Patel AT, Brashear A, Evatt M, Rubio RG, Oh CK, Snyder D, Shears G, Comella C.

Mov Disord Clin Pract. 2018 Apr 26;5(3):273-282. doi: 10.1002/mdc3.12613. eCollection 2018 May-Jun.

5.

Plasmodium falciparum Falcipain-2a Polymorphisms in Southeast Asia and Their Association With Artemisinin Resistance.

Siddiqui FA, Cabrera M, Wang M, Brashear A, Kemirembe K, Wang Z, Miao J, Chookajorn T, Yang Z, Cao Y, Dong G, Rosenthal PJ, Cui L.

J Infect Dis. 2018 Jul 2;218(3):434-442. doi: 10.1093/infdis/jiy188.

PMID:
29659945
6.

ATP1A3-Related Neurologic Disorders.

Brashear A, Sweadner KJ, Cook JF, Swoboda KJ, Ozelius L.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2008 Feb 7 [updated 2018 Feb 22].

7.

A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystonia.

Lew MF, Brashear A, Dashtipour K, Isaacson S, Hauser RA, Maisonobe P, Snyder D, Ondo W.

Int J Neurosci. 2018 Jul;128(7):619-626. doi: 10.1080/00207454.2017.1406935. Epub 2018 Jan 17.

PMID:
29343142
8.

Efficacy and safety of abobotulinumtoxinA in spastic lower limb: Randomized trial and extension.

Gracies JM, Esquenazi A, Brashear A, Banach M, Kocer S, Jech R, Khatkova S, Benetin J, Vecchio M, McAllister P, Ilkowski J, Ochudlo S, Catus F, Grandoulier AS, Vilain C, Picaut P; International AbobotulinumtoxinA Adult Lower Limb Spasticity Study Group.

Neurology. 2017 Nov 28;89(22):2245-2253. doi: 10.1212/WNL.0000000000004687. Epub 2017 Nov 1.

9.

Rehabilitation plus OnabotulinumtoxinA Improves Motor Function over OnabotulinumtoxinA Alone in Post-Stroke Upper Limb Spasticity: A Single-Blind, Randomized Trial.

Devier D, Harnar J, Lopez L, Brashear A, Graham G.

Toxins (Basel). 2017 Jul 11;9(7). pii: E216. doi: 10.3390/toxins9070216.

10.

Dose-Dependent Effects of AbobotulinumtoxinA (Dysport) on Spasticity and Active Movements in Adults With Upper Limb Spasticity: Secondary Analysis of a Phase 3 Study.

O'Dell MW, Brashear A, Jech R, Lejeune T, Marque P, Bensmail D, Ayyoub Z, Simpson DM, Volteau M, Vilain C, Picaut P, Gracies JM.

PM R. 2018 Jan;10(1):1-10. doi: 10.1016/j.pmrj.2017.06.008. Epub 2017 Jun 19.

PMID:
28634000
11.

Efficacy and Safety of AbobotulinumtoxinA (Dysport) for the Treatment of Hemiparesis in Adults With Upper Limb Spasticity Previously Treated With Botulinum Toxin: Subanalysis From a Phase 3 Randomized Controlled Trial.

Marciniak C, McAllister P, Walker H, Brashear A, Edgley S, Deltombe T, Khatkova S, Banach M, Gul F, Vilain C, Picaut P, Grandoulier AS, Gracies JM; International AbobotulinumtoxinA Adult Upper Limb Spasticity Study Group.

PM R. 2017 Dec;9(12):1181-1190. doi: 10.1016/j.pmrj.2017.06.007. Epub 2017 Jun 16.

12.

Further evaluation of the NWF filter for the purification of Plasmodium vivax-infected erythrocytes.

Li J, Tao Z, Li Q, Brashear A, Wang Y, Xia H, Fang Q, Cui L.

Malar J. 2017 May 17;16(1):201. doi: 10.1186/s12936-017-1855-3.

13.

Research conference summary from the 2014 International Task Force on ATP1A3-Related Disorders.

Rosewich H, Sweney MT, DeBrosse S, Ess K, Ozelius L, Andermann E, Andermann F, Andrasco G, Belgrade A, Brashear A, Ciccodicola S, Egan L, George AL Jr, Lewelt A, Magelby J, Merida M, Newcomb T, Platt V, Poncelin D, Reyna S, Sasaki M, Sotero de Menezes M, Sweadner K, Viollet L, Zupanc M, Silver K, Swoboda K.

Neurol Genet. 2017 Mar 2;3(2):e139. doi: 10.1212/NXG.0000000000000139. eCollection 2017 Apr.

14.

Head drop after botox: Electrodiagnostic evaluation of iatrogenic botulinum toxicity.

Szuch E, Caress JB, Paudyal B, Brashear A, Cartwright MS, Strowd RE 3rd.

Clin Neurol Neurosurg. 2017 May;156:1-3. doi: 10.1016/j.clineuro.2017.02.012. Epub 2017 Mar 6.

PMID:
28273554
15.

Genome-wide association analysis identifies genetic loci associated with resistance to multiple antimalarials in Plasmodium falciparum from China-Myanmar border.

Wang Z, Cabrera M, Yang J, Yuan L, Gupta B, Liang X, Kemirembe K, Shrestha S, Brashear A, Li X, Porcella SF, Miao J, Yang Z, Su XZ, Cui L.

Sci Rep. 2016 Oct 3;6:33891. doi: 10.1038/srep33891.

16.

Poster 289 Patient Registry of Spasticity Care World Data Analysis Based on Physician Experience.

Esquenazi A, Lee S, Mayer NH, Brashear A, Francisco GE, Yablon EE, Garreta R, Wissel J, Molteni F.

PM R. 2016 Sep;8(9S):S254. doi: 10.1016/j.pmrj.2016.07.462. Epub 2016 Sep 24. No abstract available.

PMID:
27673047
17.

Poster 288 Efficacy and Safety of Repeated AbobotulinumtoxinA Injections in Adults with Lower Limb Spasticity.

Gracies JM, Esquenazi A, Brashear A, Edgley SR, O'Dell M, Hedera P, Rubin BS, Picaut P.

PM R. 2016 Sep;8(9S):S254. doi: 10.1016/j.pmrj.2016.07.461. Epub 2016 Sep 24. No abstract available.

PMID:
27673046
18.

ATP1A3 Mutation in Adult Rapid-Onset Ataxia.

Sweadner KJ, Toro C, Whitlow CT, Snively BM, Cook JF, Ozelius LJ, Markello TC, Brashear A.

PLoS One. 2016 Mar 18;11(3):e0151429. doi: 10.1371/journal.pone.0151429. eCollection 2016.

19.

A dystonia-like movement disorder with brain and spinal neuronal defects is caused by mutation of the mouse laminin β1 subunit, Lamb1.

Liu YB, Tewari A, Salameh J, Arystarkhova E, Hampton TG, Brashear A, Ozelius LJ, Khodakhah K, Sweadner KJ.

Elife. 2015 Dec 24;4. pii: e11102. doi: 10.7554/eLife.11102.

20.

Artemisinin resistance at the China-Myanmar border and association with mutations in the K13 propeller gene.

Wang Z, Wang Y, Cabrera M, Zhang Y, Gupta B, Wu Y, Kemirembe K, Hu Y, Liang X, Brashear A, Shrestha S, Li X, Miao J, Sun X, Yang Z, Cui L.

Antimicrob Agents Chemother. 2015 Nov;59(11):6952-9. doi: 10.1128/AAC.01255-15. Epub 2015 Aug 31.

21.

Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial.

Gracies JM, Brashear A, Jech R, McAllister P, Banach M, Valkovic P, Walker H, Marciniak C, Deltombe T, Skoromets A, Khatkova S, Edgley S, Gul F, Catus F, De Fer BB, Vilain C, Picaut P; International AbobotulinumtoxinA Adult Upper Limb Spasticity Study Group.

Lancet Neurol. 2015 Oct;14(10):992-1001. doi: 10.1016/S1474-4422(15)00216-1. Epub 2015 Aug 26.

PMID:
26318836
22.

Novel mutations in ATP1A3 associated with catastrophic early life epilepsy, episodic prolonged apnea, and postnatal microcephaly.

Paciorkowski AR, McDaniel SS, Jansen LA, Tully H, Tuttle E, Ghoneim DH, Tupal S, Gunter SA, Vasta V, Zhang Q, Tran T, Liu YB, Ozelius LJ, Brashear A, Sweadner KJ, Dobyns WB, Hahn S.

Epilepsia. 2015 Mar;56(3):422-30. doi: 10.1111/epi.12914. Epub 2015 Feb 5.

23.

Rapid-onset dystonia-parkinsonism associated with the I758S mutation of the ATP1A3 gene: a neuropathologic and neuroanatomical study of four siblings.

Oblak AL, Hagen MC, Sweadner KJ, Haq I, Whitlow CT, Maldjian JA, Epperson F, Cook JF, Stacy M, Murrell JR, Ozelius LJ, Brashear A, Ghetti B.

Acta Neuropathol. 2014 Jul;128(1):81-98. doi: 10.1007/s00401-014-1279-x. Epub 2014 May 7.

24.

Distinct neurological disorders with ATP1A3 mutations.

Heinzen EL, Arzimanoglou A, Brashear A, Clapcote SJ, Gurrieri F, Goldstein DB, Jóhannesson SH, Mikati MA, Neville B, Nicole S, Ozelius LJ, Poulsen H, Schyns T, Sweadner KJ, van den Maagdenberg A, Vilsen B; ATP1A3 Working Group.

Lancet Neurol. 2014 May;13(5):503-14. doi: 10.1016/S1474-4422(14)70011-0. Review.

25.

Heterogeneity in primary dystonia: lessons from THAP1, GNAL, and TOR1A in Amish-Mennonites.

Saunders-Pullman R, Fuchs T, San Luciano M, Raymond D, Brashear A, Ortega R, Deik A, Ozelius LJ, Bressman SB.

Mov Disord. 2014 May;29(6):812-8. doi: 10.1002/mds.25818. Epub 2014 Feb 5.

26.

Cognitive impairment in rapid-onset dystonia-parkinsonism.

Cook JF, Hill DF, Snively BM, Boggs N, Suerken CK, Haq I, Stacy M, McCall WV, Ozelius LJ, Sweadner KJ, Brashear A.

Mov Disord. 2014 Mar;29(3):344-50. doi: 10.1002/mds.25790. Epub 2014 Jan 16.

27.

ATP1A3 mutations: what is the phenotype?

Brashear A, Ozelius LJ, Sweadner KJ.

Neurology. 2014 Feb 11;82(6):468-9. doi: 10.1212/WNL.0000000000000113. Epub 2014 Jan 15. No abstract available.

PMID:
24431297
28.

Commentary.

Brashear A.

Mov Disord. 2013 Dec;28(14):1939. doi: 10.1002/mds.25774. No abstract available.

PMID:
24323532
29.

Coding for the use of botulinum toxin for movement disorders.

Brashear A, Bushong L.

Continuum (Minneap Minn). 2013 Oct;19(5 Movement Disorders):1406-15. doi: 10.1212/01.CON.0000436164.71565.c5. No abstract available.

PMID:
24092297
30.

A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia.

Evidente VG, Fernandez HH, LeDoux MS, Brashear A, Grafe S, Hanschmann A, Comella CL.

J Neural Transm (Vienna). 2013 Dec;120(12):1699-707. doi: 10.1007/s00702-013-1048-3. Epub 2013 Jun 19.

31.

Cost-effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upper-limb post-stroke spasticity in Scotland.

Doan QV, Gillard P, Brashear A, Halperin M, Hayward E, Varon S, Lu ZJ.

Eur J Neurol. 2013 May;20(5):773-80. doi: 10.1111/ene.12062. Epub 2012 Dec 24.

PMID:
23278954
32.

Efficacy, tolerability, and immunogenicity of onabotulinumtoxina in a randomized, double-blind, placebo-controlled trial for cervical dystonia.

Charles D, Brashear A, Hauser RA, Li HI, Boo LM, Brin MF; CD 140 Study Group.

Clin Neuropharmacol. 2012 Sep-Oct;35(5):208-14.

PMID:
22948497
33.

Psychiatric disorders in rapid-onset dystonia-parkinsonism.

Brashear A, Cook JF, Hill DF, Amponsah A, Snively BM, Light L, Boggs N, Suerken CK, Stacy M, Ozelius L, Sweadner KJ, McCall WV.

Neurology. 2012 Sep 11;79(11):1168-73. doi: 10.1212/WNL.0b013e3182698d6c. Epub 2012 Aug 29.

34.

ATP1A3 mutations in infants: a new rapid-onset dystonia-Parkinsonism phenotype characterized by motor delay and ataxia.

Brashear A, Mink JW, Hill DF, Boggs N, McCall WV, Stacy MA, Snively B, Light LS, Sweadner KJ, Ozelius LJ, Morrison L.

Dev Med Child Neurol. 2012 Nov;54(11):1065-7. doi: 10.1111/j.1469-8749.2012.04421.x. Epub 2012 Aug 28. Review.

35.

New triggers and non-motor findings in a family with rapid-onset dystonia-parkinsonism.

Barbano RL, Hill DF, Snively BM, Light LS, Boggs N, McCall WV, Stacy M, Ozelius L, Sweadner KJ, Brashear A.

Parkinsonism Relat Disord. 2012 Jul;18(6):737-41. doi: 10.1016/j.parkreldis.2012.03.020. Epub 2012 Apr 24.

36.

Patient registry of outcomes in spasticity care.

Esquenazi A, Mayer N, Lee S, Brashear A, Elovic E, Francisco GE, Yablon S; PROS Study Group.

Am J Phys Med Rehabil. 2012 Sep;91(9):729-46. doi: 10.1097/PHM.0b013e31824fa9ca.

PMID:
22469872
37.

Relationship between disability and health-related quality of life and caregiver burden in patients with upper limb poststroke spasticity.

Doan QV, Brashear A, Gillard PJ, Varon SF, Vandenburgh AM, Turkel CC, Elovic EP.

PM R. 2012 Jan;4(1):4-10. doi: 10.1016/j.pmrj.2011.10.001. Epub 2011 Dec 24.

PMID:
22200567
38.

Comment: The new mentoring and team leadership.

Brashear A.

Neurology. 2011 Aug 16;77(7):685. doi: 10.1212/WNL.0b013e31822d6c39. Epub 2011 Jul 27. No abstract available.

PMID:
21795648
39.

A diagnostic test to distinguish psychogenic dystonia from organic dystonia?

Chen R, Brashear A.

Neurology. 2011 Feb 15;76(7):590-1. doi: 10.1212/WNL.0b013e31820d8b61. No abstract available.

PMID:
21321331
40.

Botulinum toxin type A: Exploring new indications.

Brashear A.

Drugs Today (Barc). 2010 Sep;46(9):671-82. doi: 10.1358/dot.2010.46.9.1524356. Review.

PMID:
20967299
41.

Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.

Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, Orlova O, Timerbaeva S; Global Dysport Cervical Dystonia Study Group.

Parkinsonism Relat Disord. 2010 Jun;16(5):316-23. doi: 10.1016/j.parkreldis.2010.03.002. Epub 2010 Mar 31.

PMID:
20359934
42.
43.

Spasticity.

Brashear A, Lambeth K.

Curr Treat Options Neurol. 2009 May;11(3):153-61.

PMID:
19364449
44.

Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study.

Simpson DM, Gracies JM, Yablon SA, Barbano R, Brashear A; BoNT/TZD Study Team.

J Neurol Neurosurg Psychiatry. 2009 Apr;80(4):380-5. doi: 10.1136/jnnp.2008.159657. Epub 2008 Oct 31.

PMID:
18977811
45.

Clinical comparisons of botulinum neurotoxin formulations.

Brashear A.

Neurologist. 2008 Sep;14(5):289-98. doi: 10.1097/NRL.0b013e31816f2cdd. Review.

PMID:
18784598
46.

Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.

Neurology. 2008 May 6;70(19):1699-706. doi: 10.1212/01.wnl.0000311389.26145.95.

47.

Repeated treatments with botulinum toxin type a produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients.

Elovic EP, Brashear A, Kaelin D, Liu J, Millis SR, Barron R, Turkel C.

Arch Phys Med Rehabil. 2008 May;89(5):799-806. doi: 10.1016/j.apmr.2008.01.007.

PMID:
18452724
48.

Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials.

Yablon SA, Brashear A, Gordon MF, Elovic EP, Turkel CC, Daggett S, Liu J, Brin MF.

Clin Ther. 2007 Apr;29(4):683-90.

PMID:
17617291
49.

The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene.

Brashear A, Dobyns WB, de Carvalho Aguiar P, Borg M, Frijns CJ, Gollamudi S, Green A, Guimaraes J, Haake BC, Klein C, Linazasoro G, Münchau A, Raymond D, Riley D, Saunders-Pullman R, Tijssen MA, Webb D, Zaremba J, Bressman SB, Ozelius LJ.

Brain. 2007 Mar;130(Pt 3):828-35. Epub 2007 Feb 4.

PMID:
17282997
50.

Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia.

Jankovic J, Hunter C, Dolimbek BZ, Dolimbek GS, Adler CH, Brashear A, Comella CL, Gordon M, Riley DE, Sethi K, Singer C, Stacy M, Tarsy D, Atassi MZ.

Neurology. 2006 Dec 26;67(12):2233-5.

PMID:
17190952

Supplemental Content

Loading ...
Support Center